doi: 10.1016/j.ctim.2022.102830.
- PMID: 35395396
- DOI: 10.1016/j.ctim.2022.102830
Abstract
Objective: To evaluate patterns of cannabis use in patients with cutaneous lymphoma (CL), as well as the association between cannabis use and itch specifically.
Design: Cross-sectional survey created in partnership with the Cutaneous Lymphoma Foundation (CLF).
Setting: The online survey was distributed electronically via email to the CLF listserv and links posted to social media over a 2-week period. Main Outcome Measures Respondents were classified as current cannabis users, prior users, and never users. A visual analog scale (VAS) was used to assess itching severity, improvement of itch, and interest in learning about cannabis.
Results: A total of 119 patient responses (61% female, mean age 59y) were included in analysis. The majority had mycosis fungoides or Sézary syndrome (74%; 88/119) and early stage (IA-IIA) disease (56%; 48/86). Mean VAS itch score was 3.2 + 2.8 for the cohort. Over half (55%; 60/110) reported ever having used cannabis, with 22% (24/110) endorsing current cannabis use. Common methods of cannabis use were smoking (54%) and vaporizing (46%). 25% (6/24) of current users reported using cannabis specifically to treat itch; these respondents noted that cannabis resulted in moderate improvement of itching (mean 6.6/10). There was strong interest in learning more about cannabis and cancer, and most desired this information from their CL doctor/nurse.
Conclusions: Cannabis use is common among patients with CL, and patients report improvement of itching as a result of using cannabis. Further studies are needed to elucidate the risks and benefits of cannabis use in this patient population.
Keywords: CTCL; alternative medicine/complementary medicine; cannabis; cutaneous lymphoma; itch.
Copyright © 2022. Published by Elsevier Ltd.
Conflict of interest statement
Declarations of interest Steven A. Pergam reports support from Global Life Technologies, Inc (research grant to institution); serves on the Vaccines and Related Biological Products Advisory Committee (FDA), International Council Member (ICHS), and ACIP, Zoster Vaccine Committee (CDC); and participation in clinical trials with Chimerix and Merck. Michi M. Shinohara reports honoraria from Medscape Live (Cutaneous Malignancies Forum November 2020); participation on the Medical Advisory Council for the Cutaneous Lymphoma Foundation; and serves on the Board of Directors for the Women’s Dermatologic Society, Society of Dermatology Hospitalists, and United States Cutaneous Lymphoma Consortium. The authors have no other potential conflicts of interest to disclose.
